Abstract:Objective:To explore the feasibility of microinjection method to construct the brain organoids and glioblastoma co-culture system, and to evaluate its effect and sensitivity to temozolomide (TMZ) treatment.Methods:GBM tissue samples and adjacent tissues were obtained from patients undergoing surgical treatment in the Neurosurgery Department of Xiangya Hospital, Central South University. The brain organoid model was constructed by human induced pluripotent cell line labeled with green fluorescent protein (GFP) after 24 days of culture. The expression of different protein markers was detected by immunofluorescence staining to evaluate whether the model was successfully established. We established a three-dimensional brain organoids and glioblastoma co-culture system by injecting tumor cells derived from patient-derived tumor cells or U-251 MG into cerebral organoids, in which tumor cells were labeled with red fluorescent dye. The proliferation and infiltration of GBM cells in cerebral organoids were observed by immunofluorescence staining and H-E staining. The expression of matrix metalloproteinases (MMPs), GFAP and BrdU of tumor cells in GBM fusion brain organ was detected by immunofluorescence staining, and the morphological and structural changes were observed by H-E staining. Ten μmol/L TMZ was added into the co-culture system and GBM organoids separately for 48 h, and the expression of Caspase-3 in the two models was detected by immunofluorescence staining.Results:(1) After 24 days of organoid culture, a tissue-like structure with clear buds and stratified edges was formed. Immunofluorescence staining showed positive staining results for FOXG1, N-cadherin, Auts2, Frizzled 9, GFAP, and TUJ1, which were protein markers of forebrain, ventriculoid structure, prefrontal cortex, hippocampus, astrocyte, and neuron cells, respectively. (2) Transplanted GBM cells rapidly expanded within cerebral organoids and invaded into neural tissue. Compared with brain organoids, the expressions of MMP2 and MMP13 in GBM fused organoid tumor cells were significantly increased, while the expressions of Fibronectin, MMP3, and MMP9 were significantly decreased with statistical significance (all P<0.05). There was no significant difference in MMP10 expression ( P>0.05). The expressions of BrdU and GFAP were increased (all P<0.05). (3) Compared with GBM organoids, GBM organoid-derived cells in cerebral organoids exhibited resistance to TMZ treatment with a lower expression of Caspase-3. Conclusions:The GBM-fused brain organoid model can be successfully constructed by microinjection method. The sensitivity to TMZ of tumor tissue in this model is lower than that of GBM organoids.

Evaluation of Drug Combination for Glioblastoma Based on an Intestine-Liver Metabolic Model on Microchip.

Integrated microfluidic system for cell co-culture and simulation of drug metabolism

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma

Engineering a Brain Cancer Chip for High-throughput Drug Screening

Tumor microenvironment targeting for glioblastoma multiforme treatment via hybrid cell membrane coating supramolecular micelles

An on-chip intestine-liver model for multiple drugs absorption and metabolism behavior simulation

Construction of a novel blood brain barrier-glioma microfluidic chip model: Applications in the evaluation of permeability and anti-glioma activity of traditional Chinese medicine components

Glioma cell membrane camouflaged cinobufotalin delivery system for combinatorial orthotopic glioblastoma therapy

A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co‐Delivery of Temozolomide and a Methylguanine‐DNA Methyltransferase Inhibitor

Evaluation of nanoparticle albumin-bound paclitaxel loaded macrophages for glioblastoma treatment based on a microfluidic chip

Super-small Zwitterionic Micelles Enable the Improvement of Blood-Brain Barrier Crossing for Efficient Orthotopic Glioblastoma Combinational Therapy.

A Perfused Two-Chamber System For Anticancer Drug Screening

Assay of Glioma Cell Responses to an Anticancer Drug in a Cell-Based Microfluidic Device

Engineering a High-Throughput 3-D In Vitro Glioblastoma Model

In Vitro Glioblastoma Model on a Plate for Localized Drug Release Study from a 3D-Printed Drug-Eluted Hydrogel Mesh

Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs

Metabolic models predict fotemustine and the combination of eflornithine/rifamycin and adapalene/cannabidiol for the treatment of gliomas

Towards Personalized Medicine with a Three-Dimensional Micro-Scale Perfusion-Based Two-Chamber Tissue Model System

A biomimetic targeted nanosystem delivering synergistic inhibitors for glioblastoma immune microenvironment reprogramming and treatment

Feasibility of microinjection method to construct brain organoids and glioblastoma co-culture system and its sensitivity to chemotherapy